JPRN-UMIN000016640已完成未知
oss of response to infliximab in patients with intractable ulcerative colitis: Clinical features and outcomes. - Loss of response to infliximab in patients with intractable ulcerative colitis: Clinical features and outcomes.
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine0 个研究点目标入组 40 人开始时间: 2015年2月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who had not showed initial response to IFX before. 2) Patients who had been treated with IFX at short intervals (within 8 weeks) in their exacerbating period. 3) Patients who could not provide written informed consent before being included this study.
研究者
相似试验
已完成
不适用
Study for predictors of response to infliximab therapy for ulcerative colitislcerative colitisJPRN-UMIN000007256Kanagawa Crohn Disease Treatment Study Group50
进行中（未招募）
1 期
BackToBasic: The effect of Infliximab in patients with chronic low back pain and vertebral oedema on MRI scan.A randomized, double blind, placebo-controlled, multicenter trialon-specific chronic low back pain of more than 6 months duration. We will only investigate those who have vertebral end-plate chanages(Modic changes) on MRI.MedDRA version: 20.0Level: LLTClassification code 10008837Term: Chronic back painSystem Organ Class: 100000004859EUCTR2017-004861-29-NOFOU, Nevroklinikken, Oslo University Hospital -Ullevål126
进行中（未招募）
不适用
Invloed van behandeling met infliximab op immuuncellen in het bloed van patiënten met spondyloartritisspondyloartritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-001853-17-BEniversity Hospital Ghent
进行中（未招募）
不适用
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-000982-51-DKSchering-Plough Research Institute, a Division of Schering Corporation150
进行中（未招募）
1 期
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-000982-51-BESchering-Plough Research Institute, a Division of Schering Corporation150